Clinical trial NCT00072514 (phase 2, status: completed)
Conditions: adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, cutaneous b-cell non-hodgkin lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, hepatosplenic t-cell lymphoma, intraocular lymphoma, nodal marginal zone b-cell lymphoma, noncutaneous extranodal lymphoma, peripheral t-cell lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade iii lymphomatoid granulomatosis, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, small intestine lymphoma, splenic marginal zone lymphoma, testicular lymphoma, waldenstrom macroglobulinemia
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C88.0
Drugs: gemcitabine hydrochloride, carboplatin, dexamethasone
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, N[C@@H](CCCNC(N)=N)C(O)=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have relapsed or primary refractory lymphoid malignancy (including
             B-cell, T-cell, or Hodgkin's Disease)

          -  Revised European American classification (REAL), or World Health Organization (WHO)
             classification of patients malignancies must be provided

          -  Patients must have measurable disease defined as lesions that can be accurately
             measured in two dimensions by computed tomography (CT), magnetic resonance imaging
             (MRI), medical photograph (skin or oral lesion), plain x-ray, or other conventional
             technique and a greatest transverse diameter of 1 cm or greater; or palpable lesions
             with both diameters >= 2 cm; Note: CT scans remain the standard for evaluation of
             nodal disease

          -  Patients must have a bone marrow aspirate and biopsy within 28 days of enrollment and
             no intervening anticancer therapy

          -  Patients must have a CT of chest, abdomen, and pelvis within 28 days of enrollment;
             patients with evidence of adenopathy in the neck must have a CT of neck

          -  Patients should not have evidence active central nervous system lymphoma

          -  Patients must have a Southwest Oncology Group (SWOG) performance status of 0, 1, or 2

          -  Patients should have absolute neutrophil count (ANC) >= 1,500/uL; exception: patients
             with cytopenia thought to be due to disease in their bone marrow, that do not meet
             this criteria, may be enrolled on the protocol at the Study Chair's discretion

          -  Patients should have platelets >= 100,000/uL; exception: patients with cytopenia
             thought to be due to disease in their bone marrow, that do not meet this criteria, may
             be enrolled on the protocol at the Study Chair's discretion

          -  Serum bilirubin less than 2 times the upper limit of normal

          -  Serum creatinine less than 1.5 times the upper limit of normal and creatinine
             clearance greater than 50/ mL per minute

          -  Patients must have serum lactate dehydrogenase (LDH) performed within 14 days prior to
             treatment

          -  All patients must be informed of the investigational nature of this study and have
             given written consent in accordance with institutional and federal guidelines

          -  Must anticipate that patient will complete at least 2 cycles of chemotherapy

        Exclusion Criteria:

          -  Patients known to be human immunodeficiency virus (HIV) positive

          -  Pregnant or nursing women; men or women of reproductive potential may not participate
             unless they have agreed to use an effective contraceptive method

          -  Patients with other prior malignancies except for adequately treated basal cell
             carcinoma, squamous cell carcinoma of the skin, cervical cancer in situ, or other
             cancer from which the patient has been disease-free for 5 years or greater unless
             approved by the Principal Investigator (PI)

          -  Patients that are refractory (i.e., not responded or progressed within 6 months) to a
             carboplatin or cisplatin-based regimen or a gemcitabine-based regimen

          -  Patients with active hepatitis B virus (HBV) infection or hepatitis

          -  Patients that have other medical conditions that would contraindicate treatment with
             aggressive chemotherapy